GILD news

Latest 12 stories · newest Oct 29, 2026

GILD
Gilead Q3 Sales Rise Driven by HIV Products, Revenue Guidance Raised

Gilead Sciences reported a 13% increase in Q3 product sales to $8.3 billion and raised full-year revenue guidance, offset by a significant decline in cash balances due to acquisitions and dividends.

Earnings|Guidance|Dividend|Buyback Oct 29, 2026 sentiment +0.50 SEC filing ↗
GILD
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
News Sep 30, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
News Aug 6, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
Markets Jul 24, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
Movers Jul 21, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
Trading Ideas Jul 6, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Merck Announces FDA Approval Of KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Trodelvy, For First-Line Treatment Of Breast Cancer
News Jun 25, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer
News Jun 25, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
Biotech Jun 9, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC
Biotech Jun 8, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials
Biotech Jun 8, 2026 sentiment 0.00 Source: benzinga.com ↗
GILD
Gilead Sciences issues $3 billion in senior notes across four tranches

Gilead Sciences filed an underwriting agreement to issue $3 billion in senior notes with maturities ranging from 2028 to 2034 at rates between 4.250% and 4.900%. The debt offering provides capital financing and reflects investor demand for the biopharmaceutical company's credit.

Offering May 20, 2026 sentiment 0.00 SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same GILD feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/GILD/newsSTART FREE